Citations (107)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (20)
Brian Tomlinson, Paul Chan & Christopher Wai Kei Lam. (2022) An overview of alogliptin + pioglitazone for the treatment of type 2 diabetes. Expert Opinion on Pharmacotherapy 23:1, pages 29-42.
Read now
Read now
Daisuke Yabe & Yutaka Seino. (2016) Alogliptin for the treatment of type 2 diabetes: a drug safety evaluation. Expert Opinion on Drug Safety 15:2, pages 249-264.
Read now
Read now
Yoshifumi Saisho. (2015) Alogliptin benzoate for management of type 2 diabetes. Vascular Health and Risk Management 11, pages 229-243.
Read now
Read now
Charles Andy Schuetz, Siew Hwa Ong & Matthias Blüher. (2015) Clinical trial simulation methods for estimating the impact of DPP-4 inhibitors on cardiovascular disease. ClinicoEconomics and Outcomes Research 7, pages 313-323.
Read now
Read now
Frank Lavernia, Sarah E. Adkins & Jay H. Shubrook. (2015) Use of oral combination therapy for type 2 diabetes in primary care: Meeting individualized patient goals. Postgraduate Medicine 127:8, pages 808-817.
Read now
Read now
Robert M. Guthrie. (2015) Clinical use of dipeptidyl peptidase-4 and sodium-glucose cotransporter 2 inhibitors in combination therapy for type 2 diabetes mellitus. Postgraduate Medicine 127:5, pages 463-479.
Read now
Read now
André J Scheen. (2015) Pharmacokinetics and clinical evaluation of the alogliptin plus pioglitazone combination for type 2 diabetes. Expert Opinion on Drug Metabolism & Toxicology 11:6, pages 1005-1020.
Read now
Read now
Yutaka Seino & Daisuke Yabe. (2014) Alogliptin for the treatment of Type 2 diabetes. Expert Review of Endocrinology & Metabolism 9:6, pages 547-559.
Read now
Read now
Daniel Q Holland & Joshua J Neumiller. (2014) Alogliptin in combination with metformin and pioglitazone for the treatment of type 2 diabetes mellitus. Diabetes, Metabolic Syndrome and Obesity 7, pages 277-288.
Read now
Read now
Kohei Kaku, Mikiko Mori, Tatsuhiro Kanoo, Masafumi Katou & Yutaka Seino. (2014) Efficacy and safety of alogliptin added to insulin in Japanese patients with type 2 diabetes: a randomized, double-blind, 12-week, placebo-controlled trial followed by an open-label, long-term extension phase. Expert Opinion on Pharmacotherapy 15:15, pages 2121-2130.
Read now
Read now
Stanley Schwartz. (2014) Evidence-Based Practice Use of Incretin-Based Therapy in the Natural History of Diabetes. Postgraduate Medicine 126:3, pages 66-84.
Read now
Read now
Morgan Bron, Rajeev Ayyagari, Hari Sharma, Kristina Chen, Ana Bozas & Eric Wu. (2014) Management of Patients Using Combination Therapy With Pioglitazone and a Dipeptidyl Peptidase-4 Inhibitor: An Analysis of Initial Versus Sequential Combination Therapy. Postgraduate Medicine 126:3, pages 47-55.
Read now
Read now
Yutaka Seino & Daisuke Yabe. (2014)
Alogliptin benzoate for the treatment of type 2 diabetes. Expert Opinion on Pharmacotherapy 15:6, pages 851-863.
Read now
Read now
Annalisa Capuano, Liberata Sportiello, Maria Ida Maiorino, Francesco Rossi, Dario Giugliano & Katherine Esposito. (2013) Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy – focus on alogliptin. Drug Design, Development and Therapy 7, pages 989-1001.
Read now
Read now
Yuki Fujii, Masanori Abe, Terumi Higuchi, Mari Mizuno, Hiroko Suzuki, Shiro Matsumoto, Midori Ito, Noriaki Maruyama, Kazuyoshi Okada & Masayoshi Soma. (2013) The dipeptidyl peptidase-4 inhibitor alogliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis. Expert Opinion on Pharmacotherapy 14:3, pages 259-267.
Read now
Read now
Marc Rendell, Andjela Drincic & Radha Andukuri. (2012)
Alogliptin benzoate for the treatment of type 2 diabetes. Expert Opinion on Pharmacotherapy 13:4, pages 553-563.
Read now
Read now
Yutaka Seino, Tetsuya Fujita, Shinzo Hiroi, Masashi Hirayama & Kohei Kaku. (2011) Efficacy and safety of alogliptin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, dose-ranging comparison with placebo, followed by a long-term extension study. Current Medical Research and Opinion 27:9, pages 1781-1792.
Read now
Read now
Thomas Forst, Markolf Hanefeld & Andreas Pfützner. (2011) Review of approved pioglitazone combinations for type 2 diabetes. Expert Opinion on Pharmacotherapy 12:10, pages 1571-1584.
Read now
Read now
Curtis Triplitt, Eugenio Cersosimo & Ralph A DeFronzo. (2010) Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment. Vascular Health and Risk Management 6, pages 671-690.
Read now
Read now
Bo Ahrén. (2010) Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin. Diabetes, Metabolic Syndrome and Obesity 3, pages 31-41.
Read now
Read now
Articles from other publishers (87)
D. V. Kurkin, D. A. Bakulin, E. I. Morkovin, A. V. Strygin, Yu. V. Gorbunova, E. V. Volotova, I. E. Makarenko, V. B. Saparova, R. V. Drai & V. I. Petrov. (2023) Physiology, pharmacology and prospects for dipeptidilpeptidase-4 inhibitors use. Pharmacy & Pharmacology 11:1, pages 19-47.
Crossref
Crossref
Yu.V. Strunina & N.A. Petunina. (2023) Cost-effectiveness and budget impact analysis of fixed combination of alogliptin and pioglitazone in the treatment of type 2 diabetes mellitus. Medical Technologies. Assessment and Choice:3, pages 70.
Crossref
Crossref
Wenjia Yang, Xiaoling Cai, Simin Zhang, Xueyao Han & Linong Ji. (2020) Dipeptidyl peptidase‐4 inhibitor treatment and the risk of bullous pemphigoid and skin‐related adverse events: A systematic review and meta‐analysis of randomized controlled trials. Diabetes/Metabolism Research and Reviews 37:3.
Crossref
Crossref
Chu Lin, Xiaoling Cai, Wenjia Yang, Fang Lv, Lin Nie & Linong Ji. (2020) Age, sex, disease severity, and disease duration difference in placebo response: implications from a meta-analysis of diabetes mellitus. BMC Medicine 18:1.
Crossref
Crossref
Sushrima GanAdem Y. Dawed, Louise A. DonnellyAnand T.N. NairColin N.A. PalmerViswanathan Mohan & Ewan R. Pearson. (2020) Efficacy of Modern Diabetes Treatments DPP-4i, SGLT-2i, and GLP-1RA in White and Asian Patients With Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Diabetes Care 43:8, pages 1948-1957.
Crossref
Crossref
Kohei Kaku, Koichi Kisanuki, Mari Shibata & Takashi Oohira. (2019) Benefit-Risk Assessment of Alogliptin for the Treatment of Type 2 Diabetes Mellitus. Drug Safety 42:11, pages 1311-1327.
Crossref
Crossref
Bo Ahrén. (2019) DPP-4 Inhibition and the Path to Clinical Proof. Frontiers in Endocrinology 10.
Crossref
Crossref
Chengzhi Zhang & Guiying Yan. (2019) Synergistic drug combinations prediction by integrating pharmacological data. Synthetic and Systems Biotechnology 4:1, pages 67-72.
Crossref
Crossref
N. A. PetuninaA. L. Terekhova. (2019) Reliable choice in therapy of type 2 diabetes mellitus: focus on alogliptin. Medical Council:21, pages 138-145.
Crossref
Crossref
Ben WangYan SunYiquan SangXuekui LiuJun Liang. (2018) Comparison of dipeptidyl peptidase-4 inhibitors and pioglitazone combination therapy versus pioglitazone monotherapy in type 2 diabetes. Medicine 97:46, pages e12633.
Crossref
Crossref
Yuli Cai, Tianshu Zeng, Zhongyuan Wen & Lulu Chen. (2017) Ethnic Differences in Efficacy and Safety of Alogliptin: A Systematic Review and Meta-Analysis. Diabetes Therapy 9:1, pages 177-191.
Crossref
Crossref
N. A. Petunina, E. V. Goncharova & S. A. Potapova. (2017) CARDIOVASCULAR SAFETY OF GLIPTINS. FOCUS ON ALOGLIPTIN. Medical Council:3, pages 32-37.
Crossref
Crossref
Changyu Pan, Ping Han, Qiuhe Ji, Chengjiang Li, Juming Lu, Jinkui Yang, Wenhui Li, Jiaoe Zeng, An‐Tsz Hsieh & Juliana Chan. (2016) Efficacy and safety of alogliptin in patients with type 2 diabetes mellitus: A multicentre randomized double‐blind placebo‐controlled Phase 3 study in mainland China, Taiwan, and Hong Kong. Journal of Diabetes 9:4, pages 386-395.
Crossref
Crossref
Stephen Kay, Amanda Strickson, Jorge Puelles, Ross Selby, Eugene Benson & Keith Tolley. (2017) Comparative Effectiveness of Adding Alogliptin to Metformin Plus Sulfonylurea with Other DPP-4 Inhibitors in Type 2 Diabetes: A Systematic Review and Network Meta-Analysis. Diabetes Therapy 8:2, pages 251-273.
Crossref
Crossref
Kayo Fujita, Masayuki Kaneko & Mamoru Narukawa. (2016) Factors Related to the Glucose-Lowering Efficacy of Dipeptidyl Peptidase-4 Inhibitors: A Systematic Review and Meta-Analysis Focusing on Ethnicity and Study Regions. Clinical Drug Investigation 37:3, pages 219-232.
Crossref
Crossref
Alexander Kuhn, Jean Park, Adline Ghazi & Vanita R. Aroda. (2017) Intensifying Treatment Beyond Monotherapy in Type 2 Diabetes Mellitus: Where Do Newer Therapies Fit?. Current Cardiology Reports 19:3.
Crossref
Crossref
Caroline Dudkowski, Max Tsai, Jie Liu, Zhen Zhao, Eric Schmidt & Jeannie Xie. (2016) The pharmacokinetics and pharmacodynamics of alogliptin in children, adolescents, and adults with type 2 diabetes mellitus. European Journal of Clinical Pharmacology 73:3, pages 279-288.
Crossref
Crossref
Subodh Verma, Ronald M. Goldenberg, Deepak L. Bhatt, Michael E. Farkouh, Adrian Quan, Hwee Teoh, Kim A. Connelly, Lawrence A. Leiter & Jan O. Friedrich. (2017) Dipeptidyl peptidase-4 inhibitors and the risk of heart failure: a systematic review and meta-analysis. CMAJ Open 5:1, pages E152-E177.
Crossref
Crossref
. (2016) An update on the ‘gliptins’. Drug and Therapeutics Bulletin 54:12, pages 138-141.
Crossref
Crossref
Helene Bihan, Winda L. Ng, Dianna J. Magliano & Jonathan E. Shaw. (2016) Predictors of efficacy of GLP-1 agonists and DPP-4 inhibitors: A systematic review. Diabetes Research and Clinical Practice 121, pages 27-34.
Crossref
Crossref
Helena M. de Wit, Maarten te Groen, Maroeska M. Rovers & Cees J. Tack. (2016)
The placebo response of injectable GLP-1 receptor agonists
vs
. oral DPP-4 inhibitors and SGLT-2 inhibitors: a systematic review and meta-analysis
. British Journal of Clinical Pharmacology 82:1, pages 301-314.
Crossref
Crossref
J. Kongwatcharapong, P. Dilokthornsakul, S. Nathisuwan, A. Phrommintikul & N. Chaiyakunapruk. (2016) Effect of dipeptidyl peptidase-4 inhibitors on heart failure: A meta-analysis of randomized clinical trials. International Journal of Cardiology 211, pages 88-95.
Crossref
Crossref
Wenjia Yang, Xiaoling Cai, Xueyao Han & Linong Ji. (2016) DPP-4 inhibitors and risk of infections: a meta-analysis of randomized controlled trials. Diabetes/Metabolism Research and Reviews 32:4, pages 391-404.
Crossref
Crossref
Je-Yon Kim, Seungwon Yang, Jangik I. Lee & Min Jung Chang. (2016) Cardiovascular Effect of Incretin-Based Therapy in Patients with Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis. PLOS ONE 11:4, pages e0153502.
Crossref
Crossref
Hui WangXiufei LiuMin LongYi HuangLinlin ZhangRui ZhangYi ZhengXiaoyu LiaoYuren WangQian LiaoWenjie LiZili TangQiang TongXiaocui WangFang FangMontserrat Rojo de la VegaQin OuyangDonna D. ZhangShicang YuHongting Zheng. (2016) NRF2 activation by antioxidant antidiabetic agents accelerates tumor metastasis. Science Translational Medicine 8:334.
Crossref
Crossref
Himanshu Naik, Richard Czerniak & Majid Vakilynejad. (2016) Application of pharmacometric approaches to evaluate effect of weight and renal function on pharmacokinetics of alogliptin. British Journal of Clinical Pharmacology 81:4, pages 700-712.
Crossref
Crossref
Deborah Hinnen. (2015) Dipeptidyl Peptidase-4 Inhibitors in Diverse Patient Populations With Type 2 Diabetes. The Diabetes Educator 41:1_suppl, pages 19S-31S.
Crossref
Crossref
K. Kaku, M. Katou, M. Igeta, T. Ohira & H. Sano. (2015) Efficacy and safety of pioglitazone added to alogliptin in Japanese patients with type 2 diabetes mellitus: a multicentre, randomized, double-blind, parallel-group, comparative study. Diabetes, Obesity and Metabolism 17:12, pages 1198-1201.
Crossref
Crossref
Xiao-Wu Chen, Zhi-Xu He, Zhi-Wei Zhou, Tianxin Yang, Xueji Zhang, Yin-Xue Yang, Wei Duan & Shu-Feng Zhou. (2015) An update on the clinical pharmacology of the dipeptidyl peptidase 4 inhibitor alogliptin used for the treatment of type 2 diabetes mellitus. Clinical and Experimental Pharmacology and Physiology 42:12, pages 1225-1238.
Crossref
Crossref
Xiao-Wu Chen, Zhi-Xu He, Zhi-Wei Zhou, Tianxin Yang, Xueji Zhang, Yin-Xue Yang, Wei Duan & Shu-Feng Zhou. (2015) Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus. Clinical and Experimental Pharmacology and Physiology 42:10, pages 999-1024.
Crossref
Crossref
Sreeraj Macha, Michaela Mattheus, Sabine Pinnetti, Uli C. Broedl & Hans J. Woerle. (2015) Pharmacokinetics of Empagliflozin and Pioglitazone After Coadministration in Healthy Volunteers. Clinical Therapeutics 37:7, pages 1503-1516.
Crossref
Crossref
Jennifer D. Goldman-Levine. (2015) Combination Therapy When Metformin Is Not an Option for Type 2 Diabetes. Annals of Pharmacotherapy 49:6, pages 688-699.
Crossref
Crossref
M. E. Rotz, V. S. Ganetsky, S. Sen & T. F. Thomas. (2015) Implications of incretin-based therapies on cardiovascular disease. International Journal of Clinical Practice 69:5, pages 531-549.
Crossref
Crossref
Xiaoling Cai, Xueyao Han, Yingying Luo & Linong Ji. (2014)
Efficacy of dipeptidyl‐peptidase‐4 inhibitors and impact on
β
‐cell function in
A
sian and
C
aucasian type 2 diabetes mellitus patients: A meta‐analysis在亚洲人和白种人的2型糖尿病患者中DPP‐4抑制剂的疗效及对
β
细胞功能的影响：一项meta分析
. Journal of Diabetes 7:3, pages 347-359.
Crossref
Crossref
Gillian M. Keating. (2015) Alogliptin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus. Drugs 75:7, pages 777-796.
Crossref
Crossref
Adriane B. Marino & Sabrina W. Cole. (2014) Alogliptin. Journal of Pharmacy Practice 28:1, pages 99-106.
Crossref
Crossref
Hiromi HamamotoKoji NakanishiMitsuhiko Noda. (2015) Analyzing the Factors Contributing to Withdrawal from Insulin Therapy following Additional Administration of Alogliptin: Retrospective Study after Removing Glucotoxicity with Insulin. Japanese Clinical Medicine 6, pages JCM.S27202.
Crossref
Crossref
Joshua J. Neumiller. (2015) Incretin-Based Therapies. Medical Clinics of North America 99:1, pages 107-129.
Crossref
Crossref
Nina Aleksandrovna Petunina & Anna Leont'evna Terekhova. (2014) Alogliptin – the new member of DPP-4 inhibitors class. Obesity and metabolism 11:4, pages 25-31.
Crossref
Crossref
Morgan Bron, Craig Wilson & Penny Fleck. (2014) A Post Hoc Analysis of HbA1c, Hypoglycemia, and Weight Change Outcomes with Alogliptin vs Glipizide in Older Patients with Type 2 Diabetes. Diabetes Therapy 5:2, pages 521-534.
Crossref
Crossref
George Grunberger. (2014) Clinical utility of dipeptidyl peptidase-4 inhibitors: a descriptive summary of current efficacy trials. European Journal of Clinical Pharmacology 70:11, pages 1277-1289.
Crossref
Crossref
Joshua J. Neumiller. (2014) Efficacy and Safety of Saxagliptin as Add-On Therapy in Type 2 Diabetes. Clinical Diabetes 32:4, pages 170-177.
Crossref
Crossref
Shiying Wu, Ingrid Hopper, Marina Skiba & Henry Krum. (2014) Dipeptidyl Peptidase-4 Inhibitors and Cardiovascular Outcomes: Meta-Analysis of Randomized Clinical Trials with 55,141 Participants. Cardiovascular Therapeutics 32:4, pages 147-158.
Crossref
Crossref
Michael C. Mathers, Sommer D. Zarbock & Emily E. Sutton. (2013) New and Future Medications for the Treatment of Type 2 Diabetes Mellitus. American Journal of Lifestyle Medicine 8:4, pages 260-280.
Crossref
Crossref
Shikhar Agarwal, Akhil Parashar & Venu Menon. (2014) Meta-Analysis of the Cardiovascular Outcomes with Dipeptidyl Peptidase 4 Inhibitors: Validation of the Current FDA Mandate. American Journal of Cardiovascular Drugs 14:3, pages 191-207.
Crossref
Crossref
Bethany P Cummings, Ahmed Bettaieb, James L Graham, Kimber Stanhope, Fawaz G Haj & Peter J Havel. (2014) Administration of pioglitazone alone or with alogliptin delays diabetes onset in UCD-T2DM rats. Journal of Endocrinology 221:1, pages 133-144.
Crossref
Crossref
Serge A. Jabbour, Elise Hardy, Jennifer Sugg & Shamik Parikh,. (2014) Dapagliflozin Is Effective as Add-on Therapy to Sitagliptin With or Without Metformin: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study. Diabetes Care 37:3, pages 740-750.
Crossref
Crossref
Mitsuyoshi Takahara, Toshihiko Shiraiwa, Naoto Katakami, Hideaki Kaneto, Taka-aki Matsuoka & Iichiro Shimomura. (2014) Efficacy of adding once- and thrice-daily voglibose in Japanese type 2 diabetic patients treated with alogliptin. Endocrine Journal 61:5, pages 447-456.
Crossref
Crossref
Shohei Sakata, Yasuko Mera, Yukiharu Kuroki, Reiko Nashida, Makoto Kakutani & Takeshi Ohta. (2014)
Combination Therapy of an Intestine-Specific Inhibitor of Microsomal Triglyceride Transfer Protein and Peroxisome Proliferator-Activated Receptor
γ
Agonist in Diabetic Rat
. Journal of Diabetes Research 2014, pages 1-7.
Crossref
Crossref
M. Monami, I. Dicembrini & E. Mannucci. (2014) Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials. Diabetes, Obesity and Metabolism 16:1, pages 48-56.
Crossref
Crossref
Asres Berhan & Yifru Berhan. (2013) Efficacy of alogliptin in type 2 diabetes treatment: a meta-analysis of randomized double-blind controlled studies. BMC Endocrine Disorders 13:1.
Crossref
Crossref
M. Alba, B. Ahrén, S. E. Inzucchi, Y. Guan, M. Mallick, L. Xu, E. A. O'Neill, D. E. Williams-Herman, K. D. Kaufman & B. J. Goldstein. (2013) Sitagliptin and pioglitazone provide complementary effects on postprandial glucose and pancreatic islet cell function. Diabetes, Obesity and Metabolism 15:12, pages 1101-1110.
Crossref
Crossref
Jaime A. Davidson. (2013) The Placement of DPP-4 Inhibitors in Clinical Practice Recommendations for the Treatment of Types 2 Diabetes. Endocrine Practice 19:6, pages 1050-1061.
Crossref
Crossref
Courtney I. Jarvis, Adriana Cabrera & Derek Charron. (2013) Alogliptin. Annals of Pharmacotherapy 47:11, pages 1532-1539.
Crossref
Crossref
Dennis J. Cada, Terri L. LevienDanial E. Baker. (2013) Alogliptin. Hospital Pharmacy 48:7, pages 580-592.
Crossref
Crossref
W. B. White, R. Pratley, P. Fleck, M. Munsaka, M. Hisada, C. Wilson & V. Menon. (2013) Cardiovascular safety of the dipetidyl peptidase‐4 inhibitor alogliptin in type 2 diabetes mellitus. Diabetes, Obesity and Metabolism 15:7, pages 668-673.
Crossref
Crossref
Y. G. Kim, S. Hahn, T. J. Oh, S. H. Kwak, K. S. Park & Y. M. Cho. (2013) Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis. Diabetologia 56:4, pages 696-708.
Crossref
Crossref
Naoto Katakami, Tomoya Mita, Hidenori Yoshii, Tomio Onuma, Hideaki Kaneto, Takeshi Osonoi, Toshihiko Shiraiwa, Keisuke Kosugi, Yutaka Umayahara, Tsunehiko Yamamoto, Hiroki Yokoyama, Nobuichi Kuribayashi, Hideaki Jinnouchi, Masahiko Gosho, Hirotaka Watada & Iichiro Shimomura. (2013) Rationale, Design, and Baseline Characteristics of a Trial for the Prevention of Diabetic Atherosclerosis Using a DPP-4 Inhibitor: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A). Journal of Atherosclerosis and Thrombosis 20:12, pages 893-902.
Crossref
Crossref
Yutaka Seino, Shinzo Hiroi, Masashi Hirayama & Kohei Kaku. (2012) Efficacy and safety of alogliptin added to sulfonylurea in Japanese patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled trial with an open‐label, long‐term extension study. Journal of Diabetes Investigation 3:6, pages 517-525.
Crossref
Crossref
K. Gooßen & S. Gräber. (2012) Longer term safety of dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta‐analysis. Diabetes, Obesity and Metabolism 14:12, pages 1061-1072.
Crossref
Crossref
Y. Seino, Y. Miyata, S. Hiroi, M. Hirayama & K. Kaku. (2012) Efficacy and safety of alogliptin added to metformin in Japanese patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled trial with an open‐label, long‐term extension study. Diabetes, Obesity and Metabolism 14:10, pages 927-936.
Crossref
Crossref
Vanita R. Aroda, Robert R. Henry, Jenny Han, Wenying Huang, Mary Beth DeYoung, Tamara Darsow & Byron J. Hoogwerf. (2012) Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors: Meta-Analysis and Systematic Review. Clinical Therapeutics 34:6, pages 1247-1258.e22.
Crossref
Crossref
A.J. Scheen. (2012) DPP-4 inhibitors in the management of type 2 diabetes: A critical review of head-to-head trials. Diabetes & Metabolism 38:2, pages 89-101.
Crossref
Crossref
William T. Cefalu. (2012) Evolving Treatment Strategies for the Management of Type 2 Diabetes. The American Journal of the Medical Sciences 343:1, pages 21-26.
Crossref
Crossref
Kohei Kaku, Masashi Hirayama & Emiko Komura. (2012) Alogliptin-Pioglitazone Combination Therapy: A Rational Approach to Treating Type 2 Diabetes Mellitus. Combination Products in Therapy 2:1.
Crossref
Crossref
Jay S. Skyler. 2012. Atlas of Diabetes. Atlas of Diabetes
375
417
.
E. Bosi, G. C. Ellis, C. A. Wilson & P. R. Fleck. (2011) Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study. Diabetes, Obesity and Metabolism 13:12, pages 1088-1096.
Crossref
Crossref
B. Vergès, C. Bonnard & E. Renard. (2011) Beyond glucose lowering: Glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system. Diabetes & Metabolism 37:6, pages 477-488.
Crossref
Crossref
K. Kaku, T. Itayasu, S. Hiroi, M. Hirayama & Y. Seino. (2011) Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label long-term extension study. Diabetes, Obesity and Metabolism 13:11, pages 1028-1035.
Crossref
Crossref
Nga N Ta, Corinne A Schuyler, Yanchun Li, Maria F Lopes-Virella & Yan Huang. (2011) DPP-4 (CD26) Inhibitor Alogliptin Inhibits Atherosclerosis in Diabetic Apolipoprotein E–Deficient Mice. Journal of Cardiovascular Pharmacology 58:2, pages 157-166.
Crossref
Crossref
Roberta Baetta & Alberto Corsini. (2011) Pharmacology of Dipeptidyl Peptidase-4 Inhibitors. Drugs 71:11, pages 1441-1467.
Crossref
Crossref
K. Esposito, D. Cozzolino, G. Bellastella, M. I. Maiorino, P. Chiodini, A. Ceriello & D. Giugliano. (2011) Dipeptidyl peptidase-4 inhibitors and HbA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials. Diabetes, Obesity and Metabolism 13:7, pages 594-603.
Crossref
Crossref
Joshua J. Neumiller. (2011) Clinical Pharmacology of Incretin Therapies for Type 2 Diabetes Mellitus: Implications for Treatment. Clinical Therapeutics 33:5, pages 528-576.
Crossref
Crossref
Matteo Monami, Francesco Cremasco, Caterina Lamanna, Niccolò Marchionni & Edoardo Mannucci. (2011) Predictors of response to dipeptidyl peptidase‐4 inhibitors: evidence from randomized clinical trials. Diabetes/Metabolism Research and Reviews 27:4, pages 362-372.
Crossref
Crossref
Priscilla L Hollander, Jia Li, Robert Frederich, Elsie Allen & Roland Chen. (2011) Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus. Diabetes and Vascular Disease Research 8:2, pages 125-135.
Crossref
Crossref
Bernard Zinman. (2011) Initial Combination Therapy for Type 2 Diabetes Mellitus: Is It Ready for Prime Time?. The American Journal of Medicine 124:1, pages S19-S34.
Crossref
Crossref
Baptist Gallwitz. 2011. Diabetes - Perspectives in Drug Therapy. Diabetes - Perspectives in Drug Therapy
53
74
.
Jeff Unger. (2010) Incretins: Clinical Perspectives, Relevance, and Applications for the Primary Care Physician in the Treatment of Patients With Type 2 Diabetes Mellitus. Mayo Clinic Proceedings 85:12, pages S38-S49.
Crossref
Crossref
Nga N. Ta, Yanchun Li, Corinne A. Schuyler, Maria F. Lopes-Virella & Yan Huang. (2010) DPP-4 (CD26) inhibitor alogliptin inhibits TLR4-mediated ERK activation and ERK-dependent MMP-1 expression by U937 histiocytes. Atherosclerosis 213:2, pages 429-435.
Crossref
Crossref
Milan K. Piya, Abd A. Tahrani & Anthony H. Barnett. (2010) Emerging treatment options for type 2 diabetes. British Journal of Clinical Pharmacology 70:5, pages 631-644.
Crossref
Crossref
Lesley J. Scott. (2010) Alogliptin. Drugs 70:15, pages 2051-2072.
Crossref
Crossref
André J. Scheen. (2010) Dipeptidylpeptitase-4 Inhibitors (Gliptins). Clinical Pharmacokinetics 49:9, pages 573-588.
Crossref
Crossref
Fernando Álvarez Guisasola. (2010) Actualización sobre la última familia de fármacos orales comercializados para el tratamiento de la diabetes tipo 2: los inhibidores de la DPP-4. Aportaciones respecto a las otras familias de antidiabéticos orales. Atención Primaria 42, pages 33-40.
Crossref
Crossref
Scott D. Edmondson, Feng Xu & Joseph D. ArmstrongIIIIII. 2010. Modern Drug Synthesis. Modern Drug Synthesis
123
140
.
Baptist Gallwitz. (2010) The evolving place of incretin-based therapies in type 2 diabetes. Pediatric Nephrology 25:7, pages 1207-1217.
Crossref
Crossref
. (2010) Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiology and Drug Safety 19:4, pages i-xiii.
Crossref
Crossref
Sun Woo Kim. (2010) Triple Combination Therapy Using Metformin, Thiazolidinedione, and a GLP-1 Analog or DPP-IV Inhibitor in Patients with Type 2 Diabetes Mellitus. Korean Diabetes Journal 34:6, pages 331.
Crossref
Crossref